Loading…
3 companies · GEL, thousands · columns ordered by revenue
Only 2 of 3 peers filed FY2024. Switch to FY2019 (3 of 3).
| Line item | Aversi-Pharma | Aversi-Rational | Natusana |
|---|---|---|---|
| Total Revenue | 980,306 | 63,771 | — |
| Total COGS | -628,105 | -36,548 | — |
| Gross Profit | 352,201 | 27,223 | — |
| Gross Margin | 35.9% | 42.7% | — |
| Other Operating Income | 4,972 | — | — |
| Total Operating Expenses | -246,898 | -15,856 | — |
| EBITDA | 110,275 | 11,367 | — |
| EBITDA Margin | 11.2% | 17.8% | — |
| Total D&A | -44,917 | 0 | — |
| EBIT / Operating Income | 65,358 | 11,367 | — |
| Total Interest Income | 5,412 | 82 | — |
| Total Interest Expense | -5,815 | -159 | — |
| Total Other Income | -1,771 | 193 | — |
| Profit Before Tax | 63,184 | 11,483 | — |
| Total Income Tax | 0 | -1,018 | — |
| Net Profit / (Loss) | 63,184 | 10,465 | — |
| Net Margin | 6.4% | 16.4% | — |
Not every picked company reports every selected year — FY2024: no filing for Natusana. Those cells are left blank (no filing), not zero.
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Aversi-Rational | Pharma | 17.8% | 55th pct | 110 |
| Aversi-Pharma | Pharma | 11.2% | 43rd pct | 110 |
| Natusana | (unclassified) | — | no FY data | 1208 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.